Ozempic and Wegovy contain the same active ingredient: semaglutide. The difference between them is the approved dose and the medical indication. Ozempic is approved for type 2 diabetes at doses up to 1 mg or 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. A patient prescribed either drug is receiving semaglutide, but the insurance coverage, regulatory status, and what their doctor must document to prescribe it differ.
This distinction matters practically because it determines what you pay, what your insurer will cover, and what a prescribing clinician must justify to write the prescription.
The Regulatory Difference
The FDA approved Ozempic in December 2017 for adults with type 2 diabetes to improve blood sugar control and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The approved doses are 0.5 mg, 1 mg, and 2 mg weekly.
The FDA approved Wegovy in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. The approved dose is 2.4 mg weekly. In March 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular events in adults with obesity and established cardiovascular disease, based on the SELECT trial.
Both drugs are made by Novo Nordisk. Both use subcutaneous injection via a prefilled pen. The drugs themselves are pharmacologically identical, semaglutide, but the pens, dose increments, and labeling differ.
Off-Label Ozempic for Weight Loss
Because Ozempic was on the market before Wegovy and was frequently available when Wegovy was not, many physicians prescribed Ozempic off-label for weight loss in patients who did not have diabetes. This practice is legal: physicians can prescribe approved drugs for unapproved uses at their clinical discretion.
The clinical effect on weight loss at 2 mg Ozempic versus 2.4 mg Wegovy is probably similar but not identical. The STEP trials that established Wegovy’s efficacy used 2.4 mg. Ozempic’s maximum approved dose is 2 mg. The additional 0.4 mg likely contributes some marginal additional effect, though no trial has directly compared 2 mg and 2.4 mg semaglutide for weight loss as a primary endpoint.
Insurance and Cost
This is where the distinction has the largest practical impact.
Insurers and pharmacy benefit managers have separate coverage decisions for Ozempic and Wegovy. A patient with type 2 diabetes may have Ozempic covered under their diabetes benefits while Wegovy is excluded from their formulary under obesity benefits. The reverse can also be true. Some plans cover neither. Others cover both but with different prior authorization requirements.
The list price of Wegovy is approximately $1,349 per month. The list price of Ozempic is slightly lower. With manufacturer savings programs and insurance coverage, out-of-pocket costs vary widely. Without any coverage, Wegovy costs more annually than many surgical weight loss options.
What Patients Should Know
If you are considering semaglutide for weight loss and do not have type 2 diabetes, the prescription you need is Wegovy. If your insurer covers Ozempic but not Wegovy, your prescribing physician can discuss whether off-label Ozempic is appropriate for your situation.
If you are considering compounded semaglutide, the brand-versus-off-label distinction becomes less relevant, because compounded versions exist outside both brand names entirely. The regulatory considerations for compounded semaglutide are different and are covered in Compounded Semaglutide vs. Brand-Name Ozempic: What Is the Actual Difference?
The underlying evidence for semaglutide’s effectiveness in weight loss comes from the STEP trials, particularly STEP-1, which used the 2.4 mg Wegovy dose. For a detailed look at that evidence, see What Is Semaglutide and How Does It Work for Weight Loss?
